Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q2 FY22 results · Jul–Sep 2021
Ajanta Pharma reported revenue from operations of ₹884.80 crore (up 23.6% from Q2 FY21) and net profit of ₹195.94 crore (up 15.1% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 884.80 | 715.91 | +23.6% | 747.99 | +18.3% |
| Other income | 29.54 | 4.85 | +509.1% | 32.63 | −9.5% |
| Total income | 914.34 | 720.76 | +26.9% | 780.62 | +17.1% |
| Profit before tax | 260.42 | 249.24 | +4.5% | 220.45 | +18.1% |
| Net profit for the period | 195.94 | 170.22 | +15.1% | 173.75 | +12.8% |
| EPS, basic (₹) | 22.64 | 19.51 | +16.0% | 20.08 | +12.7% |
| Net margin (%) | 22.1 | 23.8 | 23.2 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 823.71 | 676.51 | +21.8% | 742.72 | +10.9% |
| Other income | 52.41 | 86.24 | −39.2% | 31.00 | +69.1% |
| Total income | 876.12 | 762.75 | +14.9% | 773.72 | +13.2% |
| Profit before tax | 254.79 | 308.53 | −17.4% | 233.09 | +9.3% |
| Net profit for the period | 196.85 | 225.22 | −12.6% | 193.46 | +1.8% |
| EPS, basic (₹) | 22.75 | 25.81 | −11.9% | 22.36 | +1.7% |
| Net margin (%) | 23.9 | 33.3 | 26.0 |
Consolidated
- Filed with BSE
- 01 Nov 2021, 11:48 IST
- Board meeting
- 29 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 01 Nov 2021, 11:48 IST
- Board meeting
- 29 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE